 |
Spectrum Pharmaceuticals to Present Corporate Update at the Goldman Sachs 34th Annual Global Healthcare Conference in Rancho Palos Verdes on June 11th
Jun 6, 2013
|
56.8 KB |
|
| |
HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with
fully integrated commercial and drug development operations with a
primary focus in hematology and oncology, today announced that an
overview of the Company's business strategy and commercial and
de...
|
|
Spectrum Pharmaceuticals Further Strengthens Management; Announces Appointment of Kurt Gustafson as Executive Vice President, Chief Financial Officer and Principal Accounting Officer
Jun 5, 2013
|
58.9 KB |
|
| |
Brings over 20 years of diverse experience in corporate finance,
including 18 years at Amgen during which he served for three years as
CFO of Amgen International in Europe
Most recently was CFO at Halozyme Therapeutics, Inc. (NasdaqGS:
HALO)
HEN...
|
|
Spectrum Pharmaceuticals Announces Positive Data from the BELIEF Trial Presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting
Jun 3, 2013
|
62.1 KB |
|
| |
Important clinical efficacy demonstrated with single agent belinostat
in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL)
including poor prognosis subtypes
Safety profile in patients with poor marrow reserve that allowed for
the delivery of high dose intensity treatm...
|
|
Spectrum Pharmaceuticals Highlights Six Abstracts of Clinical Data at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, May 31 — June 4, 2013
May 31, 2013
|
63.0 KB |
|
| |
HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with
fully integrated commercial and drug development operations and a
primary focus in oncology and hematology, today announced key
presentations of clinical data that included: three ZEVALIN®
(ibr...
|
|
Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2013 Global Healthcare Conference in New York City on June 5th
May 29, 2013
|
56.7 KB |
|
| |
HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with
fully integrated commercial and drug development operations with a
primary focus in hematology and oncology, today announced that an
overview of the Company's business strategy and commercial and
de...
|
|
Spectrum Pharmaceuticals to Present Corporate Update at the Deutsche Bank 38th Annual Health Care Conference in Boston on May 30th
May 23, 2013
|
56.8 KB |
|
| |
HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with
fully integrated commercial and drug development operations with a
primary focus in hematology and oncology, today announced that an
overview of the Company's business strategy and commercial and
de...
|
|
Spectrum Pharmaceuticals to Present Corporate Update at the UBS Global Healthcare Conference in New York City on May 20th
May 13, 2013
|
56.8 KB |
|
| |
HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with
fully integrated commercial and drug development operations with a
primary focus in hematology and oncology, today announced that an
overview of the Company's business strategy and commercial and
de...
|
|
Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas on May 14th
May 10, 2013
|
12.1 KB |
|
| |
HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with
fully integrated commercial and drug development operations with a
primary focus in hematology and oncology, today announced that an
overview of the Company's business strategy and commercial and
de...
|
|
Spectrum Pharmaceuticals Reports Financial Results for First Quarter 2013
May 9, 2013
|
84.9 KB |
|
| |
Total revenue for the three months ending March 31, 2013 was $38.7
million. The company recorded a GAAP EPS of ($0.05).
Pivotal data in relapsed/refractory peripheral T-cell lymphoma from
late-stage drug Belinostat to be presented as an oral presentation at
ASCO 2013; the company expec...
|
|
Spectrum Pharmaceuticals Announces First Quarter 2013 Financial Results Teleconference and Webcast
May 2, 2013
|
58.2 KB |
|
| |
HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with
fully integrated commercial and drug development operations with a
primary focus in hematology and oncology, today announced it will host a
teleconference and webcast with management to discuss the first qua...
|
|
Spectrum Pharmaceuticals Initiates Phase 2 Study of Long-Acting GCSF Drug Candidate, SPI-2012, for the Treatment of Chemotherapy-Induced Neutropenia
Apr 8, 2013
|
59.4 KB |
|
| |
In U.S.-based Phase 1 trial, SPI-2012 demonstrated increase of
neutrophil count similar to Neulasta®
(pegfilgrastim) at one-third the dose.
Pending clinical progress and regulatory approval, SPI-2012 will
enter a worldwide market estimated to be over $5 billion.
...
|
|
Spectrum Pharmaceuticals Appoints Lee F. Allen, M.D., Ph.D., Industry Veteran, as Chief Medical Officer
Mar 18, 2013
|
59.6 KB |
|
| |
Dr. Allen is a hematologist/oncologist with a strong track record
in drug development.
He joins Spectrum from AMAG Pharmaceuticals, Inc., where he had
broad strategic and leadership roles as Chief Medical Officer, heading
clinical development, medical affairs and regulatory efforts res...
|
|
Spectrum Pharmaceuticals to Present Corporate Update at the 25th Annual ROTH Conference in Laguna Niguel on March 20th
Mar 15, 2013
|
56.8 KB |
|
| |
HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with
fully integrated commercial and drug development operations with a
primary focus in hematology and oncology, today announced that an
overview of the Company's business strategy and commercial and
de...
|
|
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled® Melphalan
Mar 14, 2013
|
67.1 KB |
|
| |
Product candidate is being investigated as a conditioning treatment
prior to autologous stem cell transplant for patients with multiple
myeloma.
Melphalan has been granted Orphan designation by the FDA for this
indication.
In a previous Phase 2 study, Cap...
|
|
Spectrum Pharmaceuticals Provides Corporate Update
Mar 12, 2013
|
65.6 KB |
|
| |
HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with
fully integrated commercial and drug development operations with a
primary focus in hematology and oncology, today commented on anticipated
first quarter performance and updated its 2013 outlook for the Comp...
|
|
Spectrum Pharmaceuticals Reports Record Revenues, Profits, and Cash Generated from Operations for the Twelve-Month Period Ended December 31, 2012
Feb 21, 2013
|
89.8 KB |
|
| |
Total GAAP revenue for 2012 was $267.7 million; pro forma revenue
(including ex-US ZEVALIN® and FOLOTYN®
for the entire year) was $302 million.
GAAP Product revenues were up 41% and net income increased by 95%
in 2012.
The Company reported GAAP ...
|
|
Spectrum Pharmaceuticals to Present Corporate Update at the RBC Capital Markets Healthcare Conference in New York on February 27th
Feb 20, 2013
|
56.8 KB |
|
| |
HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with
fully integrated commercial and drug development operations with a
primary focus in hematology and oncology, today announced that an
overview of the Company's business strategy and commercial and
de...
|
|
Spectrum Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2012 Financial Results Teleconference and Webcast
Feb 12, 2013
|
58.7 KB |
|
| |
HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with
fully integrated commercial and drug development operations with a
primary focus in hematology and oncology, today announced it will host a
teleconference and webcast with management to discuss the fourth qu...
|
|
Spectrum Pharmaceuticals to Present Corporate Update at the Leerink Swann 2013 Global Healthcare Conference in New York on February 14th
Feb 7, 2013
|
56.8 KB |
|
| |
HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with
fully integrated commercial and drug development operations with a
primary focus in hematology and oncology, today announced that an
overview of the Company's business strategy and commercial and
de...
|
|
Spectrum Pharmaceuticals Acquires Rights for Apaziquone in the U.S., Europe and Other Territories from Allergan; Expects to File New Drug Application
Jan 31, 2013
|
59.7 KB |
|
| |
Based on communication with the FDA, Spectrum anticipates an
Advisory Committee meeting to review a potential NDA for apaziquone.
The Company expects to file an NDA, which Spectrum will seek to
expedite as part of a plan to achieve potential commercialization of
apaziquone in key marke...
|
|
|
